5-(1,5-dimethyl-1H-[1,2,4]triazol-3-ylamino)-2-(4-methyl-imidazol-1-yl)-benzonitrile | 1225444-48-3

• 分子结构分类: 有机化合物 - 有机杂环化合物 - 唑类
• 英文名称: 5-(1,5-dimethyl-1H-[1,2,4]triazol-3-ylamino)-2-(4-methyl-imidazol-1-yl)-benzonitrile
• 英文别名: 5-[(1,5-dimethyl-1,2,4-triazol-3-yl)amino]-2-(4-methylimidazol-1-yl)benzonitrile
• CAS: 1225444-48-3
• 化学式: C₁₅H₁₅N₇
• 分子量: 293.331
• InChiKey: FOVQDRFPTRUAKG-UHFFFAOYSA-N

计算性质

• 辛醇/水分配系数(LogP)：
  2.1
• 重原子数：
  22
• 可旋转键数：
  3
• 环数：
  3.0
• sp3杂化的碳原子比例：
  0.2
• 拓扑面积：
  84.4
• 氢给体数：
  1
• 氢受体数：
  5

反应信息

• 作为产物：
  描述：

  5-bromo-2-(4-methyl-1H-imidazol-1-yl)benzonitrile 、 1,5-二甲基-1H-[1,2,4]噻唑-3-胺 在 tris(dibenzylideneacetone)dipalladium(0) chloroform complex 、 4,5-双二苯基膦-9,9-二甲基氧杂蒽 sodium phenoxide 作用下， 以 1,4-二氧六环 为溶剂， 反应 2.0h， 以11%的产率得到5-(1,5-dimethyl-1H-[1,2,4]triazol-3-ylamino)-2-(4-methyl-imidazol-1-yl)-benzonitrile
  参考文献：
  名称：

  HETEROCYCLIC GAMMA SECRETASE MODULATORS

  摘要：

  该发明涉及治疗阿尔茨海默病、脑淀粉样血管病、遗传性淀粉样脑出血、荷兰型（HCHWA-D）、多梗塞性痴呆、拳击性痴呆和唐氏综合征的方法，包括给予化合物I的治疗有效量，其中R1、R2、R3、V、W、Y和Z如本文所定义，或者是这些化合物的药用活性酸盐。该发明还涉及这些化合物的亚属和含有它们的药物组合物，以及它们的制备方法。

  公开号：

  US20100120874A1

文献信息

• Heterocyclic gamma secretase modulators
  申请人：Hoffmann-La Roche Inc.

  公开号：US08288403B2

  公开（公告）日：2012-10-16

  The invention relates to methods for the treatment of Alzheimer's disease, cerebral amyloid angiopathy, hereditary cerebral hemorrhage with amyloidosis, Dutch-type (HCHWA-D), multi-infarct dementia, dementia pugilistica and Down syndrome which comprise administering a therapeutically effective amount of a compound of formula I wherein R1, R2, R3, V, W, Y, and Z are as defined herein or a pharmaceutically active acid addition salt of such compounds. The invention also relates to a subgenus of such compounds and pharmaceutical compositions containing them, as well as methods for their manufacture.

  本发明涉及用于治疗阿尔茨海默病、脑淀粉样血管病、遗传性淀粉样脑出血、荷兰型（HCHWA-D）、多发性梗塞性痴呆、拳击性痴呆和唐氏综合征的方法，其包括向患者施用公式I的化合物的治疗有效量，其中R1、R2、R3、V、W、Y和Z如本文所定义，或这些化合物的药物活性酸盐。本发明还涉及这些化合物的亚属和含有它们的药物组合物，以及它们的制造方法。
• US8288403B2
  申请人：——

  公开号：US8288403B2

  公开（公告）日：2012-10-16
• [EN] HETEROCYCLIC GAMMA SECRETASE MODULATORS<br/>[FR] MODULATEURS DE LA GAMMA SECRÉTASE HÉTÉROCYCLIQUE
  申请人：HOFFMANN LA ROCHE

  公开号：WO2010052199A1

  公开（公告）日：2010-05-14

  The invention relates to the use of compounds of formula wherein R1 is a five or six membered heteroaryl group, optionally substituted by one or two R'; R' is lower alkyl; R2 is hydrogen, lower alkyl, lower alkoxy, hydroxy, halogen or cyano; Z is N, C, O or S; V is N, C(R''), O or S; W is N, C(R''), O, or S; Y is N or C; with the proviso that only one of Z, V or W may be O or S; R'' is hydrogen, lower alkyl, lower alkyl substituted by halogen or hydroxy, or is C(O)O-R4; L is a bond, -(CR42)n-, -C(O)NR4-, -C(O)NR4CH2-, or -C(O)-; R4 may be the same or different and is hydrogen or lower alkyl; R3 is lower alkyl, phenyl, optionally substituted by one or more R''' or is cycloalkyl; R''' is halogen, cyano, lower alkyl, lower alkyl substituted by halogen or hydroxy, or is lower alkoxy or is C(O)O-R4; n is 1, 2 or 3; or to pharmaceutically active acid addition salts for the manufacture of medicaments for the treatment of Alzheimer's disease, cerebral amyloid angiopathy, hereditary cerebral hemorrhage with amyloidosis, Dutch-type (HCHWA-D), multi-infarct dementia, dementia pugilistica or Down syndrome.